Skip to main content
Frontiers in Immunology logoLink to Frontiers in Immunology
. 2024 Jan 24;15:1353835. doi: 10.3389/fimmu.2024.1353835

Corrigendum: Arachidonate 15-lipoxygenase-mediated production of Resolvin D5n-3 DPA abrogates pancreatic stellate cell-induced cancer cell invasion

Gabriel A Aguirre 1,, Michelle R Goulart 1,, Barts Pancreas Tissue Bank 1, Jesmond Dalli 2,*,†,, Hemant M Kocher 1,*,†,
PMCID: PMC10851079  PMID: 38333216

In the published article, there was an error in the Supplementary Material: Supplementary Methods, Page 7, at the sentence: “Identification was conducted using published criteria, briefly a minimum of six diagnostic ions in total ion count EPI spectrum, matching retention time to synthetic or authentic standards, MRM peaks with more than five data points, a signal-to-noise ratio > 3 (Supplementary Figure 2). [41]. The correct material statement appears below.

“Identification was conducted using published criteria, matching retention time to synthetic or authentic standards, MRM peaks with  more than five data points, a signal-to-noise ratio > 3 (UK/MAP). In a subset of samples the identity of these mediators was further confirmed by matching a minimum of six diagnostic ions in total ion count EPI spectrum to that of a reference standard (Supplementary Figure 2). [41]”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA

RESOURCES